Skip to main content

Sun Pharma

Pays vs peer median
×0.79
-21% premium
Sample
6
medium confidence
Last refreshed
2026-04-13

By therapeutic area

Therapeutic areaPremiumDeals
dermatology×0.796

By stage at signing

PhasePremiumDeals
phase 3×0.895

Strategy profile

Based on 5 disclosed transactions, Sun Pharma concentrates its licensing activity in Dermatology, Oncology, and WomensHealth. Sun Pharma pays a 0.79x discount to market median, with the strongest premiums in Dermatology (0.79x). Their most common deal structure is Acquisition, with an average disclosed value of $2.7B. Most recent activity: 2026.

Premium by therapeutic area

How Sun Pharma pays relative to peer medians in each TA

dermatology
6 deals0.79x
Above market (≥1.10x)At market (0.90 – 1.10x)Below market (<0.90x)

Pipeline coverage & gaps

Sun Pharma has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.

Oncology
Gap
No disclosed deals
Neurology
Gap
No disclosed deals
Immunology
Gap
No disclosed deals
Metabolic
Gap
No disclosed deals
Cardiovascular
Gap
No disclosed deals
Infectious Disease
Gap
No disclosed deals
Ophthalmology
Gap
No disclosed deals
Womens Health
Gap
No disclosed deals
Rare Disease
Gap
No disclosed deals
Hematology
Gap
No disclosed deals
Dermatology
0.79x
6 deals
Gastroenterology
Gap
No disclosed deals

Deal type breakdown

How this buyer structures its transactions

Deal typeCountAvg upfrontAvg total value
AcquisitionPrimary4$4.3B$3.3B
License1$45M$250M

Recent disclosed deals

YearAssetLicensorIndicationPhaseUpfrontTotal
2026Checkpoint oncology assetsCheckpoint Therapeuticsoncologyunknown$355M
2026Organon (full company)Organonwomen's healthapproved$11.8B$11.8B
2025deuterated JAK inhibitorConcert Pharmaceuticalsalopecia areataphase_3$576M$576M
2023alopeciaAreataConcert PharmaceuticalsalopeciaAreataphase_3$576M$576M
2022acneNuvation Bioacnephase_1$45M$250M

How this is computed

For each Sun Pharma deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.

Trimmed mean of 6 disclosed deal premiums vs. peer medians. Raw premium 0.785, clamped to [0.7, 1.5].